Skip to content

Clinical Reminders in Test Reports to Improve Guideline Compliance

Clinical Reminders in Test Reports to Improve Guideline Compliance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00414401
Enrollment
1500
Registered
2006-12-21
Start date
2001-05-31
Completion date
2006-06-30
Last updated
2015-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Congestive

Brief summary

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Detailed description

Background: Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal. Objectives: To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function. Methods: We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (\<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography Status: The project is complete.

Interventions

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Those undergoing echocardiography at one of the participating laboratories with an ejection fraction \< 45%.

Exclusion criteria

aortic stenosis, mitral stenosis

Design outcomes

Primary

MeasureTime frame
Prescription for any beta-blocker

Secondary

MeasureTime frame
Prescription for carvedilol or metoprolol succinate

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026